Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Phase 1 Sickle Cell
Interventions
DRUG

PDE9i

oral dose, every 12 hours for 28 days

DRUG

PDE9i

oral dose, every 12 hours for 28 days

DRUG

placebo for PDE9i

oral dose, every 12 hours for 28 days

DRUG

PDE9i

oral dose, every 12 hours for 28 days

Trial Locations (23)

11213

Interfaith Medical Center, Brooklyn

11238

Interfaith Medical Center, Brooklyn

20122

Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan

23298

Investigational Drug Services, Richmond

Virginia Commonwealth University, Richmond

27514

UNC Hospitals' Investigational Drug Service Pharmacy, Chapel Hill

27599

UNC School of Medicine Clinical and Translational Research Center, Chapel Hill

60612

University of Illinois at Chicago Clinical Research Center, Chicago

University of Illinois Hospital and Health Sciences System, Chicago

90146

A.O.O.R Villa Sofia - V. Cervello, Palermo

60612-5836

University of Illinois Hospital and Health Sciences System, Chicago

02118

Boston Medical Center E7E, Boston

Boston Medical Center, Boston

Boston University Medical Center, Boston

B-1070

Pfizer Clinical Research Unit, Brussels

2333 CL

Centre for Human Drug Research, Leiden

L7 8XP

Royal Liverpool and Broadgreen University Hospital Trust, Liverpool

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

SE5 9RS

King's College Hospital NHS Foundation Trust, London

W12 0HS

Imperial College Healthcare NHS Trust, London

M13 9WL

Central Manchester University Hospitals NHS Foundation Trust, Manchester

Manchester Royal Infirmary, Manchester

OX3 7LE

Oxford University Hospitals NHS Trust, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY